Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 

Fetomaternal alloimmune thrombocytopenia (FMAIT) arises when a woman develops antibodies against fetal platelet antigens inherited from the father, which are absent on the mother's platelets. This condition results in fetal thrombocytopenia (platelet count < 150,000/μL). While most cases manifest mildly with widespread petechiae and skin lesions, severe instances may lead to intracranial hemorrhage (ICH), potentially causing death or long-term disability. Unlike erythrocyte alloimmunization, FMAIT can occur in first pregnancies, often recurring with increased severity in subsequent pregnancies. It is the primary cause of severe neonatal thrombocytopenia and should not be confused with autoimmune thrombocytopenia, where both mother and fetus are affected by maternal autoantibodies. Diagnosing FMAIT presents two significant challenges. Firstly, some patients may possess uncommon antiplatelet antibodies, necessitating additional testing beyond initial checks for human platelet antigens (HPA) antibodies, such as the MAIPA test, especially when common antibodies are excluded. Additionally, false-negative results can occur in up to 30% of cases, particularly concerning HPA-1a antigen, where maternal anti-HPA-1a antibodies may not be immediately detectable but may emerge weeks or months after childbirth. Most other causes of neonatal thrombocytopenia can be ruled out through careful neonatal examination and maternal history review. Common alternative causes include infection, autoimmune thrombocytopenia, drug-induced platelet destruction, disseminated intravascular coagulation, and other conditions such as necrotizing enterocolitis, hypersplenism, Kasabach-Merritt syndrome, and thrombosis. Less frequent causes encompass genetic anomalies (e.g., congenital amegakaryocytic thrombocytopenia, congenital platelet disorder), bone marrow infiltration (e.g., bone marrow metastases, neonatal leukemia), or toxic megakaryocyte injury. Rare associations exist with conditions like preeclampsia, hypoxic-ischemic injury, and neonatal cold injury. Prenatal management strategies for pregnancies at FMAIT risk include general measures like planned delivery and avoidance of nonsteroidal anti-inflammatory drugs and aspirin. Antenatal management remains contentious, with current options including maternal intravenous immunoglobulin (IVIG), maternal steroid administration, or serial intrauterine platelet transfusions (IUPT).

• The incidence of neonatal alloimmune thrombocytopenia (NAIT) within the United States is 1 in every 1000 live births. It is the leading cause of severe thrombocytopenia (platelet count < 30 × 109/L) and intracranial hemorrhage in full-term newborns.
  

Thelansis’s “Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033